Device Trial Radar · NCT03405740
Virtual E-health System for Implantable Cardioverter Defibrillators
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,115
Actual
Start
May 1, 2020
Primary completion
Apr 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Ratika ParkashAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cardiac Arrhythmia Network of Canada; Abbott Medical Devices; Medtronic
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Canadian multicenter randomized controlled trial to assess remote patient management. Patients will be randomized to remote patient management with VIRTUES versus usual care, and will be stratified by RemoteView vs no RemoteView utilization, as well as by center.
Conditions
- Cardiac Arrhythmia
Interventions
Remote Patient ManagementDevice
1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic. 2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years. 3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit) 4. VIRTUES access
Standard of CareDevice
No intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to major adverse cardiac event (primary safety outcome)Time frame: 18 months
- Time to a device-detected event (primary efficacy outcome)Time frame: 18 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Foothills Hospital
Calgary, Alberta, Canada
Victoria Cardiac Arrhythmia Trials
Victoria, British Columbia, Canada
St. Boniface Hospital
Winnipeg, Manitoba, Canada
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.